Joinn Laboratories (China) Co (SHSE:603127) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Joinn Laboratories (China) Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Joinn Laboratories (China) Co's long-term debt to total assets ratio declined from Mar. 2023 (0.01) to Mar. 2024 (0.00). It may suggest that Joinn Laboratories (China) Co is progressively becoming less dependent on debt to grow their business.

Joinn Laboratories (China) Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Joinn Laboratories (China) Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co LT-Debt-to-Total-Asset Chart

Joinn Laboratories (China) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.03

0.01

Joinn Laboratories (China) Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	-	-

Joinn Laboratories (China) Co LT-Debt-to-Total-Asset Calculation

Joinn Laboratories (China) Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	41.925	/	10027.16
	=	0.00

Joinn Laboratories (China) Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	35.532	/	9733.254
	=	0.00

Joinn Laboratories (China) Co (SHSE:603127) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Joinn Laboratories (China) Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co (SHSE:603127) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

06127:Hong Kong

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Joinn Laboratories (China) Co (SHSE:603127) Headlines

No Headlines